Abivax S.A. (ABVX)
NASDAQ: ABVX
· Real-Time Price · USD
81.99
0.96 (1.18%)
At close: Sep 02, 2025, 3:59 PM
82.20
0.26%
Pre-market: Sep 03, 2025, 04:01 AM EDT
1.18% (1D)
| Bid | 81.69 |
| Market Cap | 6.19B |
| Revenue (ttm) | 10.79M |
| Net Income (ttm) | -135.42M |
| EPS (ttm) | -3.44 |
| PE Ratio (ttm) | -23.83 |
| Forward PE | -36.34 |
| Analyst | Buy |
| Ask | 82.14 |
| Volume | 566,820 |
| Avg. Volume (20D) | 1,454,791 |
| Open | 80.01 |
| Previous Close | 81.03 |
| Day's Range | 80.01 - 82.51 |
| 52-Week Range | 4.77 - 82.51 |
| Beta | 0.07 |
About ABVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Abivax S.A. is scheduled to release its earnings on
Mar 23, 2026,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+4.85%
Abivax shares are trading higher after Piper Sandl...
Unlock content with
Pro Subscription
1 month ago
+586%
Abivax shares are trading higher after the company announced that Obefazimod met all its key secondary endpoints. JMP Securities raised its price target on the stock from $33 to $39.
1 month ago · seekingalpha.com
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data ReadoutAbviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism modul...